Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.45 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.45 |
| ▸ | HSD17B3 | P37058 | 4/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 5/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | BRS3 | P32247 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7227676 | 1.00 | MTNR1A (0.45) | MTNR1AMTNR1BHSD17B3NOTUMMAPK1 | |
| SCHEMBL5066726 | 0.88 | MTNR1A (0.42) | MTNR1AMTNR1BHSD17B3NOTUMMAPK1 | |
| SCHEMBL14130011 | 0.81 | MAPK1 (0.58) | MTNR1AMTNR1BMAPK1EPHX2 | |
| SCHEMBL20738530 | 0.76 | NOTUM (0.56) | MTNR1AMTNR1BHSD17B3NOTUMPOLB | |
| SCHEMBL419149 | 0.76 | NOTUM (0.56) | MTNR1AMTNR1BHSD17B3NOTUMPOLB | |
| SCHEMBL20738534 | 0.76 | NOTUM (0.56) | MTNR1AMTNR1BHSD17B3NOTUMPOLB | |
| SCHEMBL16722422 | 0.72 | NOTUM (0.55) | HSD17B3NOTUMBRD4SMN1; SMN2GAA | |
| SCHEMBL16722424 | 0.72 | NOTUM (0.55) | HSD17B3NOTUMBRD4SMN1; SMN2GAA | |
| SCHEMBL11890095 | 0.71 | MTNR1A (0.40) | MTNR1AMTNR1BHSD17B3MAPK1EPHX2 | |
| SCHEMBL5068055 | 0.71 | MTNR1A (0.40) | MTNR1AMTNR1BHSD17B3MAPK1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6503900-B2 | For treatment or prevention of disorders such as obsessive-compulsive disorder, depression, anxiety, schizophrenia | WYETH | 2003-01-07 | — | — | US | disclosed |
| US-20020086860-A1 | [1,4]Diazepino [6,7,1-jk] carbazoles and derivatives | AMERICAN HOME PRODUCTS CORPORATION | 2002-07-04 | — | — | US | disclosed |
| WO-2002036596-A2 | CYCLOALKYL[b][1,4]DIAZEPINO[6,7,1-hi]INDOLES AND DERIVATIVES | WYETH (US) | 2002-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020086860-A1 | [1,4]Diazepino [6,7,1-jk] carbazoles and derivatives | GRIK1, GRIK3, GRIK4 | MTNR1A 1027/4885MTNR1B 703/4885HSD17B3 674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.